Ex­elix­is shares surge on pos­i­tive liv­er can­cer re­sults; Ra­maswamy’s My­ovant banks $140M for PhI­II

→ Shares of Ex­elix­is shot up 19% this morn­ing af­ter re­searchers de­cid­ed to end a study of cabozan­ti­nib ear­ly af­ter see­ing a sta­tis­ti­cal­ly sig­nif­i­cant and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER